• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

The decision to stop or continue ADHD medication during pregnancy and breastfeeding is challenging for women with the condition. There is a lack of information about how long-term exposure to these medications could affect the fetus.

A study recently published in Molecular Psychiatry shows that children exposed to common adhd medications medication in utero do not develop neurological developmental conditions like hearing loss or impaired vision seizures, febrile seizures, or IQ impairment. The authors acknowledge the need for more high-quality studies.

Risk/Benefit Analysis

Women who are pregnant and take ADHD medication should weigh the benefits of taking it against the possible dangers for the foetus. Doctors don't have enough data to give clear advice but they can provide information on risks and benefits to assist pregnant women to make informed choices.

A study published in Molecular Psychiatry concluded that women who were taking ADHD medication during early pregnancy did not have a higher risk of fetal malformations, or structural birth defects. Researchers conducted a large, population-based case-control study to determine the prevalence of major structural birth defects in infants born to mothers who had taken stimulants during early pregnancy, as well as those who had not. Clinical geneticists, pediatric cardiologists and other experts reviewed the cases in order to ensure that the classification was accurate and to reduce any bias.

However, the researchers' study had its limitations. In particular, they were not able to differentiate the effects of the medication from the disorder that is underlying. This limitation makes it difficult to determine whether the limited associations observed in the exposed groups are due to medication use or the confounding effect of comorbidities. The researchers did not study long-term outcomes for the offspring.

The study did reveal that infants whose mothers took ADHD medications during pregnancy were at a slightly greater risk of being admitted to the neonatal intensive care unit (NICU) than infants who were born without any medication or stopped their medications before or during pregnancy. This increase was due to central nervous system-related disorders, and the increased risk of admission did not appear to be influenced by the stimulant medication was used during pregnancy.

Women who took stimulant strongest Adhd medication medications during pregnancy also had a higher chance of having to have an emergency caesarean section or having the baby was not scoring well on the Apgar scale (less than 7). These increases did not seem to be influenced by the kind of best medication for inattentive adhd used during pregnancy.

The researchers suggest that the low risk associated with the use of ADHD medications during the early stages of pregnancy could be offset by the greater benefits to both the mother and child from continued treatment for the woman's disorder. Physicians should discuss this with their patients and, if possible, assist them in developing strategies to improve their coping abilities which can reduce the impact of her disorder on her daily life and relationships.

Medication Interactions

As more women than ever are being diagnosed with ADHD and treated with medication, the issue of whether to keep or stop treatment during pregnancy is a question that more and more physicians confront. These decisions are often taken without clear and authoritative evidence. Instead, physicians must consider their own expertise in conjunction with the experiences of other doctors, and the research on the subject.

The issue of risk for infants can be extremely difficult. The research on this issue is based on observation rather than controlled studies and the results are conflicting. Additionally, the majority of studies limit their analysis to live births, which may underestimate severe teratogenic effects that lead to abortion or termination of the pregnancy. The study discussed in this journal club addresses these issues by looking at data from both live and deceased births.

Conclusion Some studies have found an association between ADHD medications and certain birth defects, other studies have not established a link. Most studies show that there is a neutral, or somewhat negative, effect. Therefore an accurate risk-benefit analysis must be done in each instance.

It can be challenging, if not impossible for women suffering from ADHD to stop taking their medication. In a recent article published in the Archives of Women's Mental Health by psychologist Jennifer Russell, she notes that stopping ADHD medications during pregnancy can lead to depression and feelings of isolation. A decrease in medication could also impact the ability to drive safely and to perform work-related tasks which are vital aspects of daily life for those suffering from ADHD.

She suggests that women who are unsure whether to continue taking medication or stop due to pregnancy should educate family members, coworkers and acquaintances about the condition, the impact on daily functioning and the advantages of staying on the current treatment regimen. Educating them can also aid in ensuring that the woman feels supported as she struggles with her decision. Certain medications can pass through the placenta. If the patient decides to stop taking her ADHD medication while pregnant and breastfeeding, it's important to be aware that the medication may be transferred to her baby.

Risk of Birth Defects

As the use and misuse of ADHD medications to treat the symptoms of attention deficit disorder hyperactivity disorder (ADHD) increases the concern over the possible effects of the drugs on the fetuses. A study that was published in the journal Molecular Psychiatry adds to the existing knowledge on this subject. Utilizing two huge data sets, researchers were able to examine more than 4.3 million pregnancies and see whether stimulant medication use increased the risk of birth defects. While the overall risk remains low, the scientists found that exposure in the first trimester to ADHD medicines was associated with an increase in the risk of certain heart defects, such as ventriculoseptal defect (VSD).

The researchers of the study didn't discover any connection between early medication usage and other congenital anomalies, such as facial deformities or club feet. The findings are in line with previous studies showing the presence of a small, but significant increase in the risk of heart malformations among women who started taking ADHD medications prior to pregnancy. The risk was higher in the latter half of pregnancy, as many women are forced to stop taking their medication.

Women who were taking ADHD medication in the first trimester were more likely to require a caesarean birth, have an insufficient Apgar after delivery and have a baby who needed breathing assistance when they were born. The authors of the study were not able to remove bias in selection since they limited their study to women with no other medical conditions that could have contributed to the findings.

Researchers hope that their research will inform physicians when they meet pregnant women. The researchers suggest that, while discussing benefits and risks are important, the decision regarding whether or not to stop medication should be made according to the severity of each woman's ADHD symptoms and the needs of the woman.

The authors caution that, even though stopping the medication is an option to consider, it is not advised because of the high incidence of depression and other mental disorders in women who are expecting or have recently given birth. Further, research shows that women who stop taking their medications will have a difficult time adjusting to a life without them after the baby is born.

Nursing

It can be overwhelming becoming a mother. Women who suffer from ADHD may face a lot of challenges when they must manage their symptoms, go to doctor appointments, prepare for the birth of a child and adjust to a new routine. Many women choose to continue taking their ADHD medication during pregnancy.

The risk to nursing infant is low because the majority of stimulant medication is absorbed through breast milk at low levels. The amount of exposure to medications will differ based on dosage and frequency of administration as well as time of day. Additionally, individual medications enter the body of the baby differently through the gastrointestinal tract as well as breast milk. The impact of this on a newborn is not well understood.

Because of the lack of research, some doctors may be inclined to discontinue stimulant drugs during the course of pregnancy. This is a difficult choice for the patient, who must balance the benefits of keeping her medication against the potential risks to the foetus. In the meantime, until more information is available, GPs may inquire about pregnant patients if they have a background of ADHD or if they plan to take medication during the perinatal stage.

A growing number of studies have shown that the majority of women are able to safely continue their ADHD medication during pregnancy and breastfeeding. In the end, many patients choose to do so and, in consultation with their physician, they have found that the benefits of maintaining their current medication exceed any risk.

Women with adhd medication ritalin who are planning to nurse should seek advice from an expert psychiatrist prior to becoming pregnant. They should discuss the medication they are taking with their physician and discuss the pros and cons for continuing treatment. This includes non-pharmacological methods. Psychoeducation is also required to help pregnant people with ADHD be aware of their symptoms and the underlying disorder and learn about treatments and to reinforce existing strategies for managing. This should be a multidisciplinary approach with the GP as well as obstetricians, psychiatry and obstetricians. The pregnancy counselling should consist of the discussion of a treatment plan for both the mother and child, and monitoring for signs of deterioration, and, if necessary, adjustments to the medication regimen.